Parker Waichman LLP Headlines by Topic
CellCept
CellCept Associated with Anemia
Aug 14, 2009
| Parker Waichman LLP
CellCept has been associated with a severe type of anemia, the Food & Drug Administration (FDA) warned today. CellCept's label has been revised...
CellCept, Other Organ Rejection Drugs Tied to Opportunistic Infections
Jul 14, 2009
| Parker Waichman LLP
Labels for the drugs CellCept, Rapamune, Myfortic, Sandimmune and Neoral are being updated to reflect a higher risk of opportunistic...
CellCept Label Changed to Reflect Risk of PML
Jun 30, 2008
| Parker Waichman LLP
The maker of CellCept, Swiss Drug Maker Roche, has informed healthcare providers that it has modified the "Warnings" and "Adverse...
FDA Reposts CellCept Warning, Pregnancy-Organ Transplant Drug Risk Link
May 22, 2008
| Parker Waichman LLP
The Food and Drug Administration (FDA) Friday reposted an earlier notice warning that Swiss drug makers Roche and Novartis drugs prescribed for organ...
FDA Issues Second CellCept Warning
May 18, 2008
| Parker Waichman LLP
The Food and Drug Administration (FDA) issued another warning Friday that Roche and Novartis drugs prescribed to organ transplant patients can cause...
CellCept Gets New FDA Warning on Miscarriage, Birth Defects
Oct 29, 2007
| Parker Waichman LLP
CellCept, a drug used to prevent organ rejection after a transplant, has been linked to an increased risk of miscarriage and birth defects. The...
Page 1/1
